RxDoctor Payments Data

Stormy Gilbert

Family · Cape Carteret, NCNPI 1205344389

Payments from drug & device makers

$746in general payments, 2019–2025

Across 28 payments — averaging $26.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$163
  • AstraZeneca$142
  • GSK$115
  • Lilly USA, LLC$94
  • Sanofi Pasteur Inc.$56
  • Novo Nordisk$51
  • plus $124 from 7 others

What the payments were for

  • Food & beverage$746100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$746 in reported general payments places this provider in the 65th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$24,937
Medicare patients
89
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$33,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$16,066
Advair HfaFluticasone Propion/Salmeterol12$5,028
Albuterol Sulfate HfaAlbuterol Sulfate54$1,499
Pimecrolimus12$1,462
Lidocaine15$1,266
Omeprazole61$1,018
Lisinopril90$784
Levothyroxine Sodium74$730
Potassium Chloride22$624
Pantoprazole Sodium39$606
Montelukast Sodium37$534
Propranolol Hcl ErPropranolol Hcl18$521
Atorvastatin Calcium60$493
Venlafaxine Hcl ErVenlafaxine Hcl19$426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$51$33,40430 claims
GSKTrelegy Ellipta$115$16,06614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,522 family providers in North Carolina.

Other family in Cape Carteret

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →